Immune Modulation as a Treatment for Abdominal Aortic Aneurysms
- PMID: 29599276
- PMCID: PMC5880296
- DOI: 10.1161/CIRCRESAHA.118.312870
Immune Modulation as a Treatment for Abdominal Aortic Aneurysms
Abstract
In the United States, over 200,000 new patients are diagnosed with abdominal aortic aneurysm (AAA) each year. Consequently, over 40,000 highly morbid aortic reconstructions are performed each year to prevent aneurysm rupture, a catastrophic event associated with near-certain mortality. No pharmaceutical currently exists to slow aneurysm growth, but a 50% reduction in diameter growth per annum could halve the number of aortic reconstructions required. Therefore, successful use of cell therapy to modulate chronic inflammation hallmark to AAA to slow diameter expansion represents a potentially paradigm-altering treatment.
Keywords: angiotensin II; aortic aneurysm, abdominal; doxycycline; matrix metalloproteinases; risk factors.
Conflict of interest statement
The authors have no relevant financial conflicts of interest to the information presented in this manuscript
References
-
- Chang TW, Gracon AS, Murphy MP, Wilkes DS. Exploring autoimmunity in the pathogenesis of abdominal aortic aneurysms. American journal of physiology. Heart and circulatory physiology. 2015;309:H719–727. - PubMed
-
- Green LA, Wang SK, Kusumanchi P, Zhang L, CC B, Murphy MP. Defects in Tr1 Cell Immune Regulation are Associated with Abdominal Aortic Aneurysm Pathogenesis (In Review) Circulation research. 2017
-
- Drewe CJ, Parker LP, Kelsey LJ, Norman PE, Powell JT, Doyle BJ. Haemodynamics and stresses in abdominal aortic aneurysms: A fluid-structure interaction study into the effect of proximal neck and iliac bifurcation angle. Journal of biomechanics. 2017;60:150–156. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
